Fu Mengjun, Li Meiyan, Xian Yiyong, Yu Zhiqiang, Zhang Haorun, Choi Joanne, Niu Lingling, Wang Xiaoying, Zhou Xingtao
Weifang Eye Hospital, Weifang, China.
Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Front Med (Lausanne). 2022 Apr 13;9:780000. doi: 10.3389/fmed.2022.780000. eCollection 2022.
To investigate the 2-year visual quality of Evolution Implantable Collamer Lens (EVO-ICL) and small incision lenticule extraction (SMILE) for the correction of low myopia.
In this prospective study, we included 25 eyes of 25 patients (7 men) who underwent EVO-ICL and 36 eyes of 36 patients (16 men) who underwent SMILE between January 2018 and December 2018. Subjective and objective visual outcomes were compared between ICL and SMILE. All patients were followed for 2 years.
At the postoperative 2-year visit, the percentage of patients with uncorrected distance visual acuity (UDVA) greater than or equal to preoperative corrected distance visual acuity (CDVA) was comparable in the ICL group (80%, 20/25) and SMILE group (88.89%, 32/36). Spherical equivalent (SE) was within ± 0.50 D in 96% (24/25) of the ICL group and 94.44% (34/36) of the SMILE group. No eyes lost more than 2 lines of CDVA. Postoperative high-order aberrations (HOAs) were significantly increased in the ICL group ( < 0.01) and in the SMILE group ( < 0.01). The most common visual complaint was halo after ICL and starburst after SMILE. There was no correlation between HOAs and visual complaints ( > 0.05).
Evolution Implantable Collamer Lens provides comparable safety, efficacy, long-term visual stability, and high patient satisfaction when compared to SMILE in correcting low myopia. EVO-ICL could be a favorable alternative for low myopia.
KEY MESSAGES WHAT WAS KNOWN?: •Visual outcomes of Evolution Implantable Collamer Lens (EVO-ICL) versus small incision lenticule extraction (SMILE) for correction of mild myopia remain unclear.
WHAT THIS PAPER ADDS?: •Evolution Implantable Collamer Lens (EVO-ICL) provides comparable safety, efficacy, long-term visual stability, and high patient satisfaction when compared to small incision lenticule extraction (SMILE) in correcting low myopia.•The most common visual complaint was halo after ICL and starburst after SMILE.
研究用于矫正低度近视的Evolution可植入式角膜胶原晶状体(EVO-ICL)和小切口透镜切除术(SMILE)的2年视觉质量。
在这项前瞻性研究中,我们纳入了2018年1月至2018年12月期间接受EVO-ICL手术的25例患者(7例男性)的25只眼以及接受SMILE手术的36例患者(16例男性)的36只眼。比较了ICL组和SMILE组的主观和客观视觉结果。所有患者均随访2年。
术后2年随访时,未矫正远视力(UDVA)大于或等于术前矫正远视力(CDVA)的患者百分比在ICL组(80%,20/25)和SMILE组(88.89%,32/36)中相当。ICL组96%(24/25)和SMILE组94.44%(34/36)的等效球镜度(SE)在±0.50 D以内。没有眼睛的CDVA下降超过2行。术后高阶像差(HOA)在ICL组(<0.01)和SMILE组(<0.01)中均显著增加。最常见的视觉主诉是ICL术后的光晕和SMILE术后的星芒状。HOA与视觉主诉之间无相关性(>0.05)。
与SMILE相比,Evolution可植入式角膜胶原晶状体在矫正低度近视时具有相当的安全性、有效性、长期视觉稳定性和较高的患者满意度。EVO-ICL可能是低度近视的一种理想替代方案。
关键信息 已知内容:•Evolution可植入式角膜胶原晶状体(EVO-ICL)与小切口透镜切除术(SMILE)矫正轻度近视的视觉结果仍不清楚。
•与小切口透镜切除术(SMILE)相比,Evolution可植入式角膜胶原晶状体(EVO-ICL)在矫正低度近视时具有相当的安全性、有效性、长期视觉稳定性和较高的患者满意度。•最常见的视觉主诉是ICL术后的光晕和SMILE术后的星芒状。